|
1
|
Zheng R, Zeng H, Zuo T, Zhang S, Qiao Y,
Zhou Q and Chen W: Lung cancer incidence and mortality in China,
2011. Thorac Cancer. 7:94–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rusch VW: Stage III non-small cell lung
cancer. Semin Respir Crit Care Med. 37:727–735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mellor AL and Munn DH: IDO expression by
dendritic cells: Tolerance and tryptophan catabolism. Nat Rev
Immunol. 4:762–774. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamazaki F, Kuroiwa T, Takikawa O and Kido
R: Human indolylamine 2,3-dioxygenase. Its tissue distribution, and
characterization of the placental enzyme. Biochem J. 230:635–638.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grohmann U, Fallarino F and Puccetti P:
Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol.
24:242–248. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirata F, Ohnishi T and Hayaishi O:
Indoleamine 2,3-dioxygenase. Characterization and properties of
enzyme O2- complex. J Biol Chem. 252:4637–4642. 1977.PubMed/NCBI
|
|
7
|
Uyttenhove C, Pilotte L, Théate I,
Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ:
Evidence for a tumoral immune resistance mechanism based on
tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med.
9:1269–1274. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karanikas V, Zamanakou M, Kerenidi T,
Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI and Germenis AE:
Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer
Biol Ther. 6:1258–1262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen IC, Lee KH, Hsu YH, Wang WR, Chen CM
and Cheng YW: Expression pattern and clinicopathological relevance
of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase
protein in colorectal cancer. Dis Markers. 2016:81697242016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feder-Mengus C, Wyler S, Hudolin T, Ruszat
R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A,
Gasser TC, et al: High expression of indoleamine 2,3-dioxygenase
gene in prostate cancer. Eur J Cancer. 44:2266–2275. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bi WW, Zhang WH, Yin GH, Luo H, Wang SQ,
Wang H, Li C, Yan WQ and Nie DZ: Analysis of indoleamine 2–3
dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by
immunohistochemistry. Asian Pac J Cancer Prev. 15:5535–5538. 2014.
View Article : Google Scholar
|
|
12
|
Liu J, Zhang H, Jia L and Sun H: Effects
of Treg cells and IDO on human epithelial ovarian cancer cells
under hypoxic conditions. Mol Med Rep. 11:1708–1714. 2015.
|
|
13
|
Creelan BC, Antonia S, Bepler G, Garrett
TJ, Simon GR and Soliman HH: Indoleamine 2,3-dioxygenase activity
and clinical outcome following induction chemotherapy and
concurrent chemoradiation in Stage III non-small cell lung cancer.
Oncoimmunology. 2:e234282013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ino K, Yoshida N, Kajiyama H, Shibata K,
Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S,
et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator
for endometrial cancer. Br J Cancer. 95:1555–1561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takao M, Okamoto A, Nikaido T, Urashima M,
Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, et
al: Increased synthesis of indoleamine-2,3-dioxygenase protein is
positively associated with impaired survival in patients with
serous-type, but not with other types of, ovarian cancer. Oncol
Rep. 17:1333–1339. 2007.PubMed/NCBI
|
|
16
|
Fus LP and Górnicka B: Role of
angiogenesis in urothelial bladder carcinoma. Cent European J Urol.
69:258–263. 2016.PubMed/NCBI
|
|
17
|
Cox G, Walker RA, Andi A, Steward WP and
O'Byrne KJ: Prognostic significance of platelet and microvessel
counts in operable non-small cell lung cancer. Lung Cancer.
29:169–177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pereira T, Dodal S, Tamgadge A, Bhalerao S
and Tamgadge S: Quantitative evaluation of microvessel density
using CD34 in clinical variants of ameloblastoma: An
immunohistochemical study. J Oral Maxillofac Pathol. 20:51–58.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D,
Yang D, Feng J and Yan X: Endothelial CD146 is required for in
vitro tumor-induced angiogenesis: The role of a disulfide bond in
signaling and dimerization. Int J Biochem Cell Biol. 41:2163–2172.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin EJ, Choi YA, Sonn JK and Kang SS:
Suppression of ADAM 10-induced Delta-1 shedding inhibits cell
proliferation during the chondro-inhibitory action of TGF-beta3.
Mol Cells. 24:139–147. 2007.PubMed/NCBI
|
|
21
|
Scharl A, Vierbuchen M, Conradt B, Moll W,
Würz H and Bolte A: Immunohistochemical detection of progesterone
receptor in formalin-fixed and paraffin-embedded breast cancer
tissue using a monoclonal antibody. Arch Gynecol Obstet. 247:63–71.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weidner N, Folkman J, Pozza F, Bevilacqua
P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis:
A new significant and independent prognostic indicator in
early-stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jinek M and Doudna JA: A three-dimensional
view of the molecular machinery of RNA interference. Nature.
457:405–412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lares MR, Rossi JJ and Ouellet DL: RNAi
and small interfering RNAs in human disease therapeutic
applications. Trends Biotechnol. 28:570–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burnett JC, Rossi JJ and Tiemann K:
Current progress of siRNA/shRNA therapeutics in clinical trials.
Biotechnol J. 6:1130–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Liu Y, Zhang G, Shi J, Zhang X,
Zheng X, Jiang AT, Zhang ZX, Johnston N, Siu KS, et al: Synergic
silencing of costimulatory molecules prevents cardiac allograft
rejection. J Transl Med. 12:1422014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vakili S, Ebrahimi SS, Sadeghi A,
Gorgani-Firuzjaee S, Beigy M, Pasalar P and Meshkani R:
Hydrodynamic-based delivery of PTP1B shRNA reduces plasma glucose
levels in diabetic mice. Mol Med Rep. 7:211–216. 2013.
|
|
29
|
Caldas H, Holloway MP, Hall BM, Qualman SJ
and Altura RA: Survivin-directed RNA interference cocktail is a
potent suppressor of tumour growth in vivo. J Med Genet.
43:119–128. 2006. View Article : Google Scholar
|
|
30
|
Shirakawa K, Tsuda H, Heike Y, Kato K,
Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, et
al: Absence of endothelial cells, central necrosis, and fibrosis
are associated with aggressive inflammatory breast cancer. Cancer
Res. 61:445–451. 2001.PubMed/NCBI
|
|
31
|
Sood AK, Fletcher MS, Zahn CM, Gruman LM,
Coffin JE, Seftor EA and Hendrix MJ: The clinical significance of
tumor cell-lined vasculature in ovarian carcinoma: Implications for
anti-vasculogenic therapy. Cancer Biol Ther. 1:661–664. 2002.
View Article : Google Scholar
|
|
32
|
Sharma N, Seftor RE, Seftor EA, Gruman LM,
Heidger PM Jr, Cohen MB, Lubaroff DM and Hendrix MJ: Prostatic
tumor cell plasticity involves cooperative interactions of distinct
phenotypic subpopulations: Role in vasculogenic mimicry. Prostate.
50:189–201. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Passalidou E, Trivella M, Singh N,
Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P,
Ratcliffe C, et al: Vascular phenotype in angiogenic and
non-angiogenic lung non-small cell carcinomas. Br J Cancer.
86:244–249. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Tredget EE, Ghaffari A, Lin X,
Kilani RT and Ghahary A: Local expression of indoleamine
2,3-dioxygenase protects engraftment of xenogeneic skin substitute.
J Invest Dermatol. 126:128–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nonaka H, Saga Y, Fujiwara H, Akimoto H,
Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O and Suzuki M:
Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of
ovarian cancer through inhibition of natural killer cell function
and angiogenesis promotion. Int J Oncol. 38:113–120. 2011.
|
